Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3423-3432

  Homma, Shinsuke ^a   Ishii, Yukio ^a   Morishima, Yuko ^a   Yamadori, Tadahiro ^a   Matsuno, Yosuke ^a   Haraguchi, Norihiro ^a   Kikuchi, Norihiro ^a   Satoh, Hiroaki ^a   Sakamoto, Tohru ^a   Hizawa, Nobuyuki ^a   Itoh, Ken ^b   Yamamoto, Masayuki ^c  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BLEOMYCIN; CISPLATIN; FLUOROURACIL; GLUTATHIONE; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2;

ADENOSQUAMOUS CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DETOXIFICATION; DNA CROSS LINKING; GENE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLEOMYCIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 66149168685     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2822     Document Type: Article

References (41)

1. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119-2152
2. Rinaldi M, Cauchi C, Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 2006;17:v64-7. (Pubitemid 43985208)
3. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004;12:955-965
4. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313-4320 (Pubitemid 24273141)
5. Young LC, Campling BG, Cole SP, et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001;7:1798-1804
6. Soini Y, Napankangas U, Jarvinen K, et al. Expression of γ-glutamyl cysteine synthetase in non-small cell lung carcinoma. Cancer 2001;92:2911-2919
7. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627 (Pubitemid 34177898)
8. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006;38:769-789
9. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004;24:7130-7139 (Pubitemid 39014439)
10. Zhang DD, Lo SC, Cross JV, et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24:10941-10953 (Pubitemid 39603148)
11. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 2004;36:1199-1207 (Pubitemid 38526313)
12. Hayashi A, Suzuki H, Itoh K, et al. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance- associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 2003;310:824-829 (Pubitemid 37188696)
13. Vollrath V, Wielandt AM, Iruretagoyena M, et al. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J 2006;395:599-609.
14. Reddy NM, Kleeberger SR, Cho HY, et al. Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants. Am J Respir Cell Mol Biol 2007;37:3-8. (Pubitemid 46999531)
15. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLOS Med 2006;3:1865-1876
16. Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-1309
17. de Jong S, Zijlstra JG, Timmer-Bosscha H, et al. Detection of DNA cross-links in tumor cells with the ethidium bromide fluorescence assay. Int J Cancer 1986;37:557-561 (Pubitemid 16108596)
18. C method. Methods 2001;25:402-408
19. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor-2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-7984
20. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353
21. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320 (Pubitemid 41130944)
22. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498
23. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003;10:159-165 (Pubitemid 36437822)
24. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43. (Pubitemid 32530848)
25. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-7523 (Pubitemid 37487173)
26. Yao KS, Godwin AK, Johnson SW, et al. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 1995;55:4367-4374
27. Cho JM, Manandhar S, Lee HR, et al. Role of Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 2008;260:96-108.
28. Das U. A radical approach to cancer. Med Sci Monit 2002;8:RA79-92. (Pubitemid 34453440)
29. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338 (Pubitemid 37328853)
30. Henkel G, Krebs B. Metallothioneins: zinc, cadmium, mercury, and copper thiolates and selenolates mimicking protein active site features-structural aspects and biological implications. Chem Rev 2004;104:801-824
31. Matsumoto Y, Oka M, Sakamoto A, et al. Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy. Anticancer Res 1997;17:3777-3780 (Pubitemid 28014939)
32. Haq F, Mahoney M, Koropatnick J. Signaling events for metallothionein induction. Mutat Res 2003;533:211-226 (Pubitemid 37487870)
33. Ohtsuji M, Katsuoka F, Kobayashi A, et al. NRF1 and NRF2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem 2008;283:33554-33562
34. 0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2Fpathw ay. J Cell Biochem 2007;102:1400-1404
35. Korenjak M, Brehm A. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev 2005;15:520-527 (Pubitemid 41262408)
36. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002;21:6908-6914 (Pubitemid 35221937)
37. Mack PC, Gandara DR, Bowen C, et al. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res 1999;5:2596-2604 (Pubitemid 29437347)
38. Russo T, Zambrano N, Esposito F, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 1995;270:29386-29391
39. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol 2000;48:190-202. (Pubitemid 30318121)
40. Lu Q, Jourd'Heuil FL, Jourd'Heuil D. Redox control of G(1)/S cell cycle regulators during nitric oxide-mediated cell cycle arrest. J Cell Physiol 2007;212:827-839
41. Reddy NM, Kleeberger SR, Bream JH, et al. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 2008;27:5821-5832